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To the Editor:
The extensive work for a new
classification of lung adenocarcinoma
by Travis et al.1 is highly appreciated.
Nevertheless, new terms and definitions
raise questions and discussions, which
should be addressed in focus of the ap-
plication of the new multidisciplinary
classification of lung adenocarcinoma to
clinical management of patients with
lung cancer worldwide.
First, the inclusion of tumor size
in solitary nodules (3 cm and 5
mm invasion) into the new classifica-
tion is questionable. A continuous de-
velopment of preinvasive lesions into
more extensive disease stages may oc-
cur, independent from the chosen size;
furthermore, size is a prognostic rele-
vant criterion within the existing tumor,
node, metastasis (TNM) system which
should not be replaced. In this context,
the terms adenocarcinoma in situ and
minimally invasive adenocarcinoma
have a potential of misguidance, espe-
cially due to their limitation on resection
specimens, which is not applicable to
small biopsies and cytological speci-
mens as well. Considering the aspect
that also small simultaneous multilocu-
lar lesions may occur, the question
arises, how multilocular synchronous le-
sions could be histologically distin-
guished from a solitary lesion in the
proposed classification. The present
term “bronchioalveolar carcinoma” is
restricted to tumors with lepidic growth,
or at least predominantly lepidic growth,
and does not address size, solitary, or—
synchronous—multiple location, which
is expressed by the TNM formula, thus
offering a clear classificatory descrip-
tion. Therefore, the relation between the
clinical TNM system and the new clas-
sification has to be clarified to avoid an
overlap f.e. in a T1a status according to
the International Association for the
Study of Lung Cancer 2007.2
For pneumologists in particular,
small biopsies are frequently the basis
for diagnosis, and a solution to render
the vague new term “favor” (non-
small cell lung cancer favor adenocar-
cinoma) more precisely could be the
addition of a quality marker for histo-
logical or cytological diagnosis as it is
available in the TNM system for the
clinical use (C1–C4).3 Using such an
adjunct, no artificial separations be-
tween small and large biopsies or new
terms would be necessary.
Christian Witt, MD, PhD
Division of Pneumology
Department of Pneumological Oncology
Charite´ - Medical University Berlin
Berlin, Germany
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Sublobar Resection of
Ground Glass
Opacity—Great Data,
but can I have More?
To the Editor:
I read with great interest the ar-
ticle by Susuki et al.1 and commend
the authors for applying formal scien-
tific methods in a prospective study to
the issue of selection of patients for
sublobar resection. These investigators
and others from Japan have led the
world in better defining the manage-
ment of these patients. Nevertheless, I
wish they had reported a few more
details.
From a statistician’s point of
view, sensitivity and specificity are
good measures, but these do not lend
themselves well to prospective appli-
cation to an individual patient, which
is the problem faced by the clinician.
Specificity tells us how often the ra-
diographic assessment will be positive
for invasion in a cohort of patients in
whom it is already known that they all
have invasion.2 A clinician, of course,
does not know whether the patient has
or does not have invasion preopera-
tively and only knows that the radio-
graphic assessment has been either
negative or positive. Thus, the clini-
cian needs to know how often the
assessment of “radiographically non-
invasive” is falsely negative. This re-
quires knowledge of the false-negative
(FN) rate of the test result (or, as some
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prefer, the less intuitive term negative
predictive value). Although the FN or
false-positive rate is sometimes criti-
cized for being influenced by the prev-
alence, this effect primarily occurs at
extremely high or low prevalence (not
in the range of prevalence among the
patients in this study). As I calculate
the results for all patients (regardless
of size), the FN rate is 5%, 9%, and
7% for the C/T ratio, tumor disappear-
ance ratio, and visual estimation meth-
ods, respectively. I wish the authors
would report the FN rates for the three
methods for tumors less than 2 cm.
They have not provided enough data to
allow this calculation to be made.
In addition, although vascular
invasion and lymphatic invasion have
been widely viewed as surrogate
markers for tumor dissemination to
nodes or distant sites in Japan, this has
been less well adopted in other parts of
the world. Furthermore, I would argue
that the issue in question is local
spread (i.e. nodal metastasis) when
considering lobar versus sublobar re-
section (if distant metastasis has oc-
curred, it will not be influenced by the
extent of local resection). Therefore, I
think that focusing on a surrogate such
as vascular or lymphatic invasion may
not be as relevant as the actual occur-
rence of nodal metastasis. I wish the
authors would specifically report the
incidence of nodal involvement for tu-
mors with a C/T ratio, tumor disap-
pearance ratio, and visual estimation
ratio of less than 0.5 (for lesions of all
sizes as well as only those 2 cm).
Once again, I wish to commend
the authors for their substantial contri-
butions to the clinical science of lung
cancer.
Frank C. Detterbeck, MD
Division of Thoracic Surgery
Department of Surgery
Yale University
New Haven, Connecticut
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JCOG0201 Defined
“Radiological Early
Peripheral Lung
Adenocarcinoma”
To the Editor:
In our article entitled, “A Pro-
spective Radiological Study of Thin-
Section Computed Tomography to
Predict Pathological Noninvasiveness
in Peripheral Clinical IA Lung Cancer
(JCOG0201),” we made a comparison
between radiological findings of
ground glass attenuation on thin-sec-
tion computed tomography and patho-
logical invasiveness such as lymph
node metastasis. Sensitivity and spec-
ificity were evaluated in this article,
and the definition of radiological early
peripheral lung cancer was clarified
for the first time. It is difficult for
readers to interpret those data because
of its unique method and mode for
defining radiological early lung can-
cer.1 However, Dr. Detterbeck’s ques-
tion definitely hit the nail of the head.
We agree with him on that most sur-
geons need information on lymph
node metastasis instead of vascular or
lymphatic invasion. We actually pre-
pared the data for submitting, but it
was not possible for the limitation of
the number of the tables. As to the
false-negative cases for invasiveness
in lung cancer 2 cm or less in size, the
following table is added (Table 1).
This table contains data on lung cancer
2.0 cm or less in size and cutoff of 0.5,
that is, the size of consolidation less
than half of the maximum tumor di-
mension. As to nodal invasion for ra-
diological early lung cancer, we are
preparing manuscript on this matter.
We are sure to submit the information
in the near future.
In addition, we have already con-
ducted phase II trial named JCOG0804
for limited surgical resection for the “ra-
diological early lung cancer” defined by
the JCOG0201. Accrual of patients has
just been completed, and we will con-
clude whether our criteria for early lung
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TABLE 1. Radiologic-Pathologic Correlation in Lung Cancer 2.0 cm or Less in Size
(Cutoff: 0.5)
Radiology (Cutoff: 0.5)a
Pathological Diagnosisb
Noninvasive Invasive
Consolidation/tumor ratio on lung window
Noninvasivea 65 2
Invasive 145 77
Sensitivity 31.0% (95% CI: 24.8–37.7)
Specificity 97.5% (95% CI: 91.2–99.7)
TDR
Noninvasivea 101 10
Invasive 109 69
Sensitivity 48.1% (95% CI: 41.2–55.1)
Specificity 87.3% (95% CI: 78.0–93.8)
Visual estimation of consolidation
Noninvasivea 84 7
Invasive 126 72
Sensitivity 40.0% (95% CI: 33.3–47.0)
Specificity 91.1% (95% CI: 82.6–96.4)
TDR, tumor disappearance ratio; CI, confidence interval.
a Cutoff for the diagnosis of radiologic noninvasive cancer is 0.5.
b Pathological noninvasive is defined as adenocarcinoma with no nodal involvement, lymphatic invasion, nor
vascular invasion.
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